Print Topic



Dosage Forms and Delivery Systems


A diverse range of dosage forms and delivery systems has been developed to provide for the care and welfare of animals. The development of dosage forms draws on the discipline of biopharmaceutics, which integrates an understanding of formulations, dissolution, stability, and controlled release (pharmaceutics); absorption, distribution, metabolism, and excretion (pharmacokinetics, PK); concentration-effect relationships and drug-receptor interactions (pharmacodynamics, PD); and treatment of the disease state (therapeutics). Formulation of a dosage form typically involves combining an active ingredient and one or more excipients; the resultant dosage form determines the route of administration and the clinical efficacy and safety of the drug. Optimization of drug doses is also critical to achieving clinical efficacy and safety. Increasingly, a PK/PD model that describes the drug response is the basis of dose optimization. The PK and PD phases are linked by the premise that free drug in the systemic circulation is in equilibrium with the receptors. The PD phase involves interaction of the drug with the receptor, which triggers post-receptor events and eventually leads to a drug effect (see Drug Concentration and Effect).

Drug delivery strategies for veterinary formulations are complicated by the diversity of species and breeds treated, the wide range in body sizes, different husbandry practices, seasonal variations, cost constraints associated with the value of the animal being treated, the persistence of residues in food and fiber (see Chemical Residues in Food and Fiber), and the level of convenience, among other factors. Innovative solutions have been developed to meet many of these challenges (eg, the convenient dosing option offered by topical spot-on formulations for treating external and internal parasites on dogs and cats, the microencapsulation of NSAID as a means of masking taste when these agents are added to the rations of horses). Unique opportunities also exist for controlled-release drug delivery systems in veterinary medicine, and many such systems are on the market. For example, controlled-release boluses have been developed for delivering antimicrobials, anthelmintics, production enhancers, nutritional supplements, and other drugs to ruminants.

Oral Dosage Forms and Delivery Systems

Oral dosage forms comprise liquids (solutions, suspensions, and emulsions), semi-solids (pastes), and solids (tablets, capsules, powders, granules, premixes, and medicated blocks).

A solution is a mixture of 2 or more components that form a single phase that is homogeneous down to the molecular level. Solutions offer several advantages over other dosage forms. Compared with solid dosage forms, solutions are absorbed faster and generally cause less irritation of the GI mucosa. Moreover, phase separation on storage is not a concern with solutions, as it may be for suspensions and emulsions. The disadvantages of solutions include susceptibility to microbial contamination and the hydrolysis in aqueous solution of susceptible active ingredients. In addition, the taste of some drugs is more unpleasant when in solution. A range of additives is used in the formulation of oral solutions, including buffers, flavors, antioxidants, and preservatives. Oral solutions provide a convenient means of drug administration to neonates and young animals.

A suspension is a coarse dispersion of insoluble drug particles, generally with a diameter exceeding 1 μm, in a liquid (usually aqueous) medium. Suspensions are useful for administering insoluble or poorly soluble drugs or when the presence of a finely divided form of the material in the GI tract is required. An example of the latter is the treatment of “frothy bloat” with dimethyl polysiloxanes, which relies on a dispersion of finely divided silica in the fore-stomach of ruminants. The taste of most drugs is less noticeable in suspension than in solution, due to the drug being less soluble in suspension. Particle size is an important determinant of the dissolution rate and bioavailability of drugs in suspension. In addition to the excipients described above for solutions, suspensions include surfactants and thickening agents. Surfactants wet the solid particles, thereby ensuring the particles disperse readily throughout the liquid. Thickening agents reduce the rate at which particles settle to the bottom of the container. Some settling is acceptable, provided the sediment can be readily dispersed when the container is shaken. Because hard masses of sediment do not satisfy this criterion, caking of suspensions is not acceptable.

An emulsion is a system consisting of 2 immiscible liquid phases, one of which is dispersed throughout the other in the form of fine droplets; droplet diameter generally ranges from 0.1–100 μm. The 2 phases of an emulsion are known as the dispersed phase and the continuous phase. Emulsions are inherently unstable and are stabilized through the use of an emulsifying agent, which prevents coalescence of the dispersed droplets. Creaming, as occurs with milk, also occurs with pharmaceutical emulsions. However, it is not a serious problem because a uniform dispersion returns upon shaking. Creaming is, nonetheless, undesirable because it is associated with an increased likelihood of the droplets coalescing and the emulsion “breaking.” Other additives include buffers, antioxidants, and preservatives. Emulsions for oral administration are usually oil (the active ingredient) in water, and facilitate the administration of oily substances such as castor oil or liquid paraffin in a more palatable form.

A paste is a 2-component semi-solid in which drug is dispersed as a powder in an aqueous or fatty base. The particle size of the active ingredient in pastes can be as large as 100 μm. The vehicle containing the drug may be water; a polyhydroxy liquid such as glycerin, propylene glycol, or polyethylene glycol; a vegetable oil; or a mineral oil. Other formulation excipients include thickening agents, cosolvents, adsorbents, humectants, and preservatives. The thickening agent may be a naturally occurring material such as acacia or tragacanth, or a synthetic or chemically modified derivative such as xanthum gum or hydroxypropylmethyl cellulose. The degree of cohesiveness, plasticity, and syringeability of pastes is attributed to the thickening agent. It may be necessary to include a cosolvent to increase the solubility of the drug. Syneresis of pastes is a form of instability in which the solid and liquid components of the formulation separate over time; it is prevented by including an adsorbent such as microcrystalline cellulose. A humectant (eg, glycerin or propylene glycol) is used to prevent the paste that collects at the nozzle of the dispenser from forming a hard crust. Microbial growth in the formulation is inhibited using a preservative. It is critical that pastes have a pleasant taste or are tasteless. Pastes are a popular dosage form for treating cats and horses, and can be easily and safely administered by owners.

A tablet consists of one or more active ingredients and numerous excipients and may be a conventional tablet that is swallowed whole, a chewable tablet, or a modified-release tablet (more commonly referred to as a modified-release bolus due to its large unit size). Conventional and chewable tablets are used to administer drugs to dogs and cats, whereas modified-release boluses are administered to cattle, sheep, and goats. The physical and chemical stability of tablets is generally better than that of liquid dosage forms. The main disadvantages of tablets are the bioavailability of poorly water-soluble drugs or poorly absorbed drugs, and the local irritation of the GI mucosa that some drugs may cause.

A capsule is an oral dosage form usually made from gelatin and filled with an active ingredient and excipients. Two common capsule types are available: hard gelatin capsules for solid-fill formulations, and soft gelatin capsules for liquid-fill or semi-solid-fill formulations. Soft gelatin capsules are suitable for formulating poorly water-soluble drugs because they afford good drug release and absorption by the GI tract. Gelatin capsules are frequently more expensive than tablets but have some advantages. For example, particle size is rarely altered during capsule manufacture, and capsules mask the taste and odor of the active ingredient and protect photolabile ingredients.

A powder is a formulation in which a drug powder is mixed with other powdered excipients to produce a final product for oral administration. Powders have better chemical stability than liquids and dissolve faster than tablets or capsules because disintegration is not an issue. This translates into faster absorption for those drugs characterized by dissolution rate-limited absorption. Unpleasant tastes can be more pronounced with powders than with other dosage forms and can be a particular concern with in-feed powders, leading to variable ingestion of the dose. Moreover, sick animals often eat less and are therefore not amenable to treatment with in-feed powder formulations. Drug powders are principally used prophylactically in feed, or formulated as a soluble powder for addition to drinking water or milk replacer. Powders have also been formulated with emulsifying agents to facilitate their administration as liquid drenches.

A granule is a dosage form consisting of powder particles that have been aggregated to form a larger mass, usually 2–4 mm in diameter. Granulation overcomes segregation of the different particle sizes during storage and/or dose administration, the latter being a potential source of inaccurate dosing. Granules and powders generally behave similarly; however, granules must deaggregate prior to dissolution and absorption.

A premix is a solid dosage form in which an active ingredient, such as a coccidiostat, production enhancer, or nutritional supplement, is formulated with excipients. Premix products are mixed homogeneously with feed at rates (when expressed on an active ingredient basis) that range from a few milligrams to ∼200 g/ton of feed. They are administered to poultry, pigs, and ruminants. The density, particle size, and geometry of the premix particles should match as closely as possible those of the feed in which the premix will be incorporated to facilitate uniform mixing. Issues such as instability, electrostatic charge, and hygroscopicity must also be addressed. The excipients present in premix formulations include carriers, liquid binders, diluents, anti-caking agents, and anti-dust agents. Carriers, such as wheat middlings, soybean mill run, and rice hulls, bind active ingredients to their surfaces and are important in attaining uniform mixing of the active ingredient. A liquid binding agent, such as a vegetable oil, should be included in the formulation whenever a carrier is used. Diluents increase the bulk of premix formulations, but unlike carriers, they do not bind the active ingredients. Examples of diluents include ground limestone, dicalcium phosphate, dextrose, and kaolin. Caking in a premix formulation may be caused by hygroscopic ingredients and is addressed by adding small amounts of anti-caking agents such as calcium silicate, silicon dioxide, and hydrophobic starch. The dust associated with powdered premix formulations can have serious implications for both operator safety and economic losses, and is reduced by including a vegetable oil or light mineral oil in the formulation. An alternate approach to overcoming dust is to granulate the premix formulation.

A medicated block is a compressed feed material that contains an active ingredient, such as a drug, anthelmintic, surfactant (for bloat prevention), or a nutritional supplement, and is commonly packaged in a cardboard box for feeding to livestock. Ruminants typically have free access to the medicated block over several days, and variable consumption may be problematic. This concern is addressed by ensuring the active ingredient is nontoxic, stable, palatable, and preferably of low solubility. In addition, excipients in the formulation modulate consumption by altering the palatability and/or the hardness of the medicated block. For example, molasses increases palatability and sodium chloride decreases it. Additionally, the incorporation of a binder such as lignin sulfonate in blocks manufactured by compression or magnesium oxide in blocks manufactured by chemical reaction, increases hardness. The hygroscopic nature of molasses in a formulation may also impact the hardness of medicated blocks and is addressed by using appropriate packaging.

Oral Modified-Release Delivery Systems

Several modified-release delivery systems have been developed that take advantage of the unique anatomy of the ruminant forestomach. Prominent among these systems are intraruminal boluses, which contain a range of active ingredients including parasiticides, nutritional supplements, anti-bloat agents, and production enhancers. They are administered using a balling gun. Most of the commercially available intra-ruminal boluses are continuous release devices that rely on erosion, diffusion from a reservoir, dissolution of a dispersed matrix, or an osmotic “driver” to release the active ingredient. The pay-out period for intra-ruminal boluses is commonly longer than 100 days. Regurgitation during rumination is prevented by the bolus having a density of ∼3 g/cm3 or a variable geometry.

Other types of oral modified-release delivery systems are also available for ruminants. For example, sustained-release boluses that deliver sulfonamides over a period of ~72 hr are available for treating cattle. In addition, sustained-release boluses containing methoprene or diflubenzuron are approved for the control of manure-breeding flies in cattle.

The intraruminal devices for supplementing ruminants with selenium, cobalt, or copper include soluble glass boluses and intraruminal pellets. Boluses of soluble glass containing selenium, cobalt, and copper are available for cattle and sheep. Because glass is susceptible to sudden changes in temperature, glass boluses should be at least 15–20°C at the time of administration to avoid fracturing, which in turn may lead to regurgitation. Glass boluses are designed to dissolve in ruminal fluids, thereby releasing the incorporated elements. The composition of the glass determines the solubility of the bolus, with an increase in the ratio of monovalent to divalent cations resulting in an increase in solubility. The glass boluses are retained in the rumen for up to 9 mo.

Intraruminal pellets containing selenium or cobalt are available for sheep. Selenium or cobalt is released over a period of ∼3 yr from the pellet matrix, which consists of compressed iron grit. When selenium or cobalt intraruminal pellets are administered alone, a “grinder” is usually co-administered to prevent the formation of calcium phosphate coatings on the surface of the pellets.

Copper capsules, which contain oxidized copper wire particles encapsulated in gelatin, are available for adult sheep and goats. After oral administration the gelatin capsule dissolves in the rumen and releases the particles of copper oxide. The particles progress to the abomasum where some are trapped in the mucosal folds and release copper.

Parenteral Dosage Forms and Delivery Systems

Parenteral dosage forms and delivery systems include injectables (ie, solutions, suspensions, emulsions, and dry powders for reconstitution), intramammary infusions, intravaginal delivery systems, and implants. Recombinant proteins and peptides as well as vaccines are specialized dosage forms, usually for parental administration.

A solution for injection is a mixture of 2 or more components that form a single phase that is homogeneous down to the molecular level. “Water for injection” is the most widely used solvent for parenteral formulations. However, a nonaqueous solvent or a mixed aqueous/nonaqueous solvent system may be necessary to stabilize drugs that are readily hydrolyzed by water or to improve solubility. A range of excipients may be included in parenteral solutions, including antioxidants, antimicrobial agents, buffers, chelating agents, inert gases, and substances for adjusting tonicity. Antioxidants maintain product stability by being preferentially oxidized over the shelf life of the product. Antimicrobial preservatives inhibit the growth of any microbes that are accidentally introduced when doses are being withdrawn from multiple-dose bottles, and they act as adjuncts in aseptic processing of products. Buffers are necessary to maintain both solubility of the active ingredient and stability of the product. Chelating agents are added to complex and thereby inactivate metals, including copper, iron, and zinc, which generally catalyze oxidative degradation of drugs. Inert gases are used to displace the air in solutions and enhance product integrity of oxygen-sensitive drugs. Isotonicity of the formulation is achieved by including a tonicity-adjusting agent. Failing to adjust the tonicity of the solution can result in the hemolysis or crenation of erythrocytes when hypotonic or hypertonic solutions, respectively, are given IV in quantities >100 mL. Injectable formulations must be sterile and free of pyrogens. Pyrogenic substances are primarily lipid polysaccharides derived from microorganisms, with those produced by gram-negative bacilli generally being most potent. Injectable solutions are very commonly used, and aqueous solutions given IM result in immediate drug absorption, provided precipitation at the injection site does not occur.

A suspension for injection consists of insoluble solid particles dispersed in a liquid medium, with the solid particles accounting for 0.5–30% of the suspension. The vehicle may be aqueous, oil, or both. Caking of injectable suspensions is minimized through the production of flocculated systems, comprising clusters of particles (flocs) held together in a loose open structure. Excipients in injectable suspensions include antimicrobial preservatives, surfactants, dispersing or suspending agents, and buffers. Surfactants wet the suspended powders and provide acceptable syringeability while suspending agents modify the viscosity of the formulation. The ease of injection and the availability of the drug in depot therapy are affected by the viscosity of the suspension and the particle size of the suspended drug. These systems afford enhanced stability to active ingredients that are prone to hydrolysis in aqueous solutions. Injectable suspensions are commonly used. Compared with that of injectable solutions, the rate of drug absorption of injectable suspensions is prolonged because additional time is required for disintegration and dissolution of the suspended drug particles. The slower release of drug from an oily suspension compared with that of an aqueous suspension is attributed to the additional time taken by drug particles suspended in an oil depot to reach the oil/water boundary and become wetted before dissolving in tissue fluids.

An emulsion for injection is a heterogeneous dispersion of one immiscible liquid in another; it relies on an emulsifying agent for stability. Parenteral emulsions are rare because it is seldom necessary to achieve an emulsion for drug administration. Untoward physiologic effects following IV administration may occur, including emboli in blood vessels if the droplets are >1 μm in diameter. Formulation options for injectable emulsions are also severely restricted because suitable stabilizers and emulsifiers are very limited. Examples of parenteral emulsions include oil-in-water sustained-release depot preparations, which are given IM, and water-in-oil emulsions of allergenic extracts, which are given SC.

A dry powder for parenteral administration is reconstituted as a solution or as a suspension immediately prior to injection. The principal advantage of this dosage form is that it overcomes the problem of instability in solution.

Intramammary infusion products to treat mastitis are available for lactating and nonlactating (dry) cows. Lactating cow intramammary infusions should demonstrate fast and even distribution of the drug and a low degree of binding to udder tissue. These properties result in lower concentrations of drug residues in the milk. By comparison, it is desirable for nonlactating cow formulations to demonstrate prolonged drug release and a high degree of binding to mammary secretions and udder tissues. Particle size is particularly important because it affects both the rate of release of the active ingredient and irritancy to the udder tissue. Drug particle size in nonlactating intramammary formulations is usually smaller than in those for lactating cows, which is critical in reducing irritancy during prolonged retention in the udder. Thickening agents are added to modify the rate of release of the suspended particles from oil formulations, and antioxidants are commonly incorporated to prevent rancidity. Mastitis infusion products are often terminally sterilized by irradiation.

Intravaginal delivery systems include controlled internal drug release (CIDR) devices, progesterone-releasing intravaginal devices (PRID), and vaginal sponges. These systems are used for estrus synchronization in sheep, goats, and cattle. Silicone is used in the manufacture of the T-shaped CIDR device and the coil-shaped PRID, whereas intravaginal sponges are made from polyurethane. The active ingredients in these systems are synthetic or natural hormones such as progesterone, methyl-acetoxy progesterone, fluorogestone acetate, or estradiol benzoate. An applicator consisting of a speculum and a separate plunger is used to insert sponges into the vaginal cavities of sheep and goats, and PRID into the vaginal cavities of cattle. A different type of applicator is used for inserting CIDR devices into the vaginal cavities of sheep, goats, and cattle. Retention in the vagina depends on either the wings (CIDR device) or the entire device (sponges and PRID) expanding. With all 3 devices, gentle pressure is exerted on the vaginal wall. Retention of the device is >95%.

The majority of implants used in veterinary medicine are compressed tablets or dispersed matrix systems in which the drug is uniformly dispersed within a nondegradable polymer. Drug release from dispersed matrix systems involves dissolution of the drug into the polymer, followed by diffusion of the drug through the polymer and partitioning from the surface of the polymer into the surrounding aqueous environment. Implants are available to increase weight gain and feed conversion efficiency in food-producing animals. These implants are typically prepared in a manner similar to tablets. One controlled-release implant consists of a cylindrical core of silicone, surrounded by an outer layer of estradiol-loaded silicone. A range of implants is available to enhance reproductive performance in breeding animals. These include ear implants containing norgestomet dispersed in polyethylene methacrylate or silicone, a biocompatible tablet implant containing deslorelin (a GnRH agonist) for use in mares that does not require removal, and a sustained-release pellet of melatonin, which is implanted in the ear of ewes to enhance breeding performance. Testosterone pellets are available for implanting in the ears of wethers at doses of 70–100 mg every 3 mo for the prevention of ulcerative posthitis.

Recombinant proteins and peptides are used in some countries for increasing feed conversion efficiency and milk production in cattle (bovine growth hormone), increasing feed conversion efficiency and producing leaner carcasses in pigs (porcine growth hormone), the chemical shearing of sheep (epidermal growth factor), reducing the incidence of skeletal weaknesses leading to leg injuries in horses (equine growth hormone), and for other uses. Recombinant proteins and peptides have been formulated as solutions, lyophilized powders, implants, and microparticles. The chemical and physical instability of recombinant proteins and peptides is a special consideration during formulation development. The major causes of chemical instability are proteolysis, deamidation, oxidation, and racemization. Causes of physical instability are aggregation, precipitation, denaturation, and adsorption to surfaces. A range of strategies has been reported for stabilizing formulations containing recombinant proteins and peptides, including the choice of carrier vehicle (eg, oleaginous vehicles), the use of lyophilization excipients, the use of stabilizers such as sugars and detergents, chemical modification of the proteins and peptides, and the use of site-directed mutagenesis to synthesize more stable proteins.

The organisms in live vaccines are subjected to freeze-drying and, less commonly, to deep freezing at ≤ −70°C. In order to maintain the viability of organisms under these conditions, the formulation includes complex mixtures of proteins, peptides or amino acids, sugars, and mineral salts. The viability of organisms is additionally protected using stabilizers such as lactose or other saccharides, skim milk, and serum.

Formulations used for inactivated and subunit vaccines consist of antigen(s), adjuvants, stabilizers, and preservatives (in the case of multiple-dose products). Inactivating agents such as phenol, thiomersal, and formaldehyde are used to kill the virus or bacteria without destroying the critical integrity of the antigens necessary to induce a protective immune response. Adjuvants enhance the immunogenicity of antigens by stimulating the immune system and prolonging antigen release. In this respect, aluminum hydroxide, aluminum phosphate, and oil emulsions are generally preferred for conferring humoral immunity, whereas saponin, quil A, and immunity stimulating complexes (ISCOMS) are preferred for conferring cell-mediated immunity.

The use of plasmid DNA vectors to express antigens in vivo for the purpose of generating immune responses is a recent development. Two delivery systems for DNA vaccines have been reported. In one system, the segment of DNA is coated with gold and administered to the patient using a “gene gun.” The other delivery system uses a viral vector or plasmid to carry the DNA segment into the patient.

Topical Dosage Forms and Delivery Systems

The topical dosage forms available for treating animals include solids (dusting powders), semi-solids (creams, ointments, and pastes), and liquids (solutions, suspension concentrates, suspoemulsions, and emulsifiable concentrates). Of special interest are transdermal delivery systems that elicit clinical responses by carrying medications across the skin barrier to the bloodstream. Examples of these are transdermal gels and patches that are used in companion animals. Also of interest are dosage forms that are unique to veterinary medicine, such as spot-on, pour-on, and backliner formulations developed for the control of parasites.

A dusting powder is a finely divided insoluble powder containing ingredients such as talc, zinc oxide, or starch. Coarse powders often have a gritty feel, whereas powders containing particles that are <20 μm in all dimensions have a smooth feel. Some dusting powders absorb moisture, which discourages bacterial growth. Others are used for their lubricant properties. The use of dusting powders is indicated on skin folds and contraindicated on wet surfaces, as caking is likely to result.

A cream is a semi-solid emulsion formulated for application to the skin or mucous membranes. Droplet diameter in topical emulsions generally ranges from 0.1–100 μm. Cream emulsions are most commonly oil-in-water but may be water-in-oil. The former readily rub into the skin (hence the term “vanishing” cream) and are removed by licking and washing. By comparison, water-in-oil emulsions are emollient and cleansing. Water-in-oil emulsions are also less greasy and spread more readily than ointments, and they soothe inflamed skin as a consequence of the water in the formulation evaporating.

An ointment is a greasy, semi-solid pre-paration that contains dissolved or dispersed drug. A range of ointment bases is used, including hydrocarbons, vegetable oils, silicones, absorption bases consisting of a mixture of hydrocarbons and lanolin, emulsifying bases consisting of a mixture of hydrocarbons and an emulsifying agent, and water-soluble bases. Ointment bases influence topical drug bioavailability via 2 mechanisms. First, their occlusive properties are responsible for hydrating the stratum corneum, which enhances the flux of drug across the skin. Second, they affect drug dissolution within the ointment and drug partitioning from the ointment into the skin. Ointments are effective emollients due to their occlusive nature. They are indicated for chronic, dry lesions and contraindicated in exudative lesions.

A paste for topical use is a stiff preparation containing a high proportion of finely powdered solids such as starch, zinc oxide, calcium carbonate, and talc. Pastes are less greasy than ointments because much of the fluid hydrocarbon fraction is absorbed onto the solid particles; they are also less occlusive than ointments. Pastes are indicated for ulcerated lesions.

A solution for topical use is a mixture of 2 or more components that form a single phase down to the molecular level. Topical solutions include eye drops, ear drops, and lotions. Eye drops are sterile liquids that contain a range of drugs, including local anesthetics, antibiotics, anti-inflammatory agents, and drugs acting on the autonomic nervous system of the eye. They are instilled onto the eyeball or within the conjunctival sac. Ear drops are solutions of drugs such as antibiotics, insecticides, or anti-inflammatory agents. The vehicle may be water, glycerol, propylene glycol, or alcohol/water mixtures. They are applied to the external auditory canal. A lotion is usually an aqueous solution (or suspension) for application to inflamed, ulcerated skin. Lotions cool the skin by evaporation of solvents, leaving a film of dry powder. Lotions are suitable for use on hairy areas and for lesions with minor exudation and ulceration.

A suspension concentrate for topical use is a mixture of insoluble, solid active ingredients, which are normally at high concentrations, in water or oil. Suspension concentrate formulations are generally water-based; the water-insoluble active ingredients and inert ingredients are of very small particle size (0.1–5 μm). Other formulation additives include suspending agents, surfactants, and other excipients to ensure the production of a shelf-stable, pourable product. Surfactants wet, disperse, and stabilize the solid particles in the continuous phase, prevent flocculation, and prevent changes in particle size. Thickening agents are included to increase the viscosity of the formulation, thereby overcoming sedimentation of the suspended particles and affording good longterm stability. Suspension concentrates are used topically as pour-ons, plunge and shower dip concentrates, and jetting fluids.

A suspoemulsion combines the elements of an emulsion and a suspension, allowing active ingredients with widely varying physical properties to be formulated in a single product. Typically, a suspoemulsion contains one or more solvent-soluble active ingredients in an emulsion phase, combined with one or more low solubility active ingredients in a continuous aqueous suspension phase.

Following dilution, an emulsifiable concentrate for topical use produces a 2-phase system involving 2 immiscible liquids, a dispersed phase consisting of fine oil droplets ranging in size from 0.5 μm to several hundred microns, and a continuous phase. Addition of an emulsifiable concentrate formulation to water results in the formation of an emulsion, which relies on surface-active agents concentrating at the oil/water interface. Active ingredients that are soluble in water-immiscible organic solvents are frequently formulated as emulsifiable concentrates. The flocculation of oil droplets in emulsifiable concentrate formulations leads to a layer of cream that can be readily dispersed by mild agitation, whereas the coalescence of droplets leads to the inversion or “breaking” of the emulsion. Water with a high content of Ca2+ and/or Mg2+ reacts with anionic surfactants in the emulsifiable concentrate formulation; this affects both spontaneity of emulsification and stability. Zinc sulfate, which is used as a dip additive to minimize the spread of dermatophilosis in sheep, also adversely affects emulsions.

A transdermal delivery gel consists of a vehicle, most commonly pluronic lecithin organogel (PLO gel), which delivers drug via the transdermal route to the bloodstream. The micellar composition of PLO gel enhances skin penetration of the pharmaceutical agent present in the formulation. PLO gel is generally well tolerated and is nontoxic if ingested. However, not all drugs are suitable for transdermal application and there are relatively few studies of the bioavailability of drugs from compounded transdermal gels. Transdermal gels are used to deliver drugs to treat several diseases in dogs and cats, including undesirable behavior, cardiac disease, and hyperthyroidism. The dose is applied to the inner surface of the pinnae, thereby offering ease of administration, especially in cats.

A transdermal delivery patch typically consists of a drug incorporated into a reservoir, a protective backing layer, a rate-limiting release membrane, and an adhesive layer for securing the patch to the skin. The physicochemical properties of a drug suitable for transdermal delivery ideally include low molecular weight (<500 daltons), high potency, water solubility (to facilitate movement of the drug out of the reservoir and to allow passage through the epidermal and dermal layers of the skin), and lipid solubility (to permit penetration of the stratum corneum of the skin). Fentanyl, a synthetic opioid agonist, is delivered by transdermal patch in dogs, cats, and horses.

The control of internal and external parasites of companion and food-producing animals has led to the development of specialized dosage forms, delivery systems, and application methods that are unique to veterinary medicine.

A spot-on formulation is a solution of active ingredient(s), which typically contains a cosolvent and a spreading agent. The active ingredients in spot-on products for flea, GI parasite, or heartworm control in dogs and cats include fipronil, imidacloprid, selamectin, pyriproxyfen, ivermectin, and moxidectin. Spot-on formulations are also available to control lice in cattle. The physicochemical properties of the active ingredient(s) are important determinants of topical or transdermal behavior. Topical activity against ectoparasites depends to some extent on the active ingredient spreading, mixing with the sebum coating the skin and hair, and forming depots in the pilosebaceous units. The mechanism of percutaneous drug absorption varies between species and is not completely understood. However, low molecular weight and a high lipid/water partition coefficient tend to favor passage of the drug through the skin.

Backliner products for sheep consist of pour-on and spray-on formulations for the control of lice and sheep blowflies. Sheep lousicides include synthetic pyrethroids, organophosphates, and insect growth regulators. These products are formulated for pour-on application within 24 hr after shearing (ie, off-shears) or spray-on application (in short-wool sheep with wool growth <6 wk, and in long-wool sheep with wool growth >6 wk). Their efficacy against lice depends on topical activity and not on percutaneous absorption of the active ingredient into the bloodstream. Translocation of the pesticide from the application site to remote sites at concentrations lethal to lice is critical to the efficacy of these products and, in the case of pour-on applications, is facilitated by the increased secretion of wool grease that occurs at shearing.

The active ingredients in sheep blowfly products include insect growth regulators, synthetic pyrethroids, and organophosphates. Following their topical application, sheep blowfly larvicides form follicular depots at the time of application and subsequently translocate as a coating on new wool growing out of the follicles.

Hand-jetting of long-wool sheep (wool growth >6 wk) is done to control lice, keds, mites, and sheep blowflies. The pesticides used include rotenone, synthetic pyrethroids, organophosphates, insect growth regulators, and macrocyclic lactones. Hand-jetting involves the use of a handpiece (or wand) to “rake” a pesticide solution into the wool along the dorsal midline and sometimes into the breech or crutch, as well as the poll. The solution is applied under pressure and penetrates to the skin.

Some of the pour-on products on the market are formulated to deliver an active ingredient percutaneously. The macrocyclic lactones ivermectin, moxidectin, doramectin, and eprinomectin are formulated as pour-on preparations for application to cattle. These formulations are usually solutions or emulsifiable concentrates for dilution with water prior to use. The principal route of percutaneous absorption for most drugs in humans is the intercellular pathway, making the intercellular lipid matrix the primary barrier to absorption. However, this may not be the case in species in which the emulsifying properties of skin secretions and the large numbers of follicles and glands per unit surface area must be taken into account (eg, cattle and sheep). Ionized solutes, for example, are reported to cross the skin of animals via shunt pathways (sweat ducts, follicles). Pour-on products are formulated to spread without run-off when applied to the skin and to be resistant to rain. The formulation also facilitates the partitioning of the drug out of the vehicle and into the skin and transport of the drug across the skin. The control of these processes is critical because some drug is required to remain at the skin if the drug is to be active against external parasites that are not blood sucking. In addition, too rapid passage of drug through the skin may result in unacceptable chemical residues in tissues or milk.

The plunge dipping of sheep and cattle for external parasites requires a dipping vat, which may be a portable unit or a permanent in-ground structure shielded from direct sunlight by roofing. A draining pen located at the exit of the vat allows dip wash draining off treated animals to return to the vat. Dip chemicals are usually formulated as aqueous solutions, emulsifiable concentrates, or suspension concentrates, all of which are diluted with water prior to use. The high costs associated with plunge dipping relate principally to the costs of chemicals for charging large vats, labor, and the disposal of the hazardous wastes. Plunge dips must be managed properly, and the pesticide maintained at the concentration recommended by the manufacturer. Dipping of sheep and cattle is associated with “stripping” of the active ingredient from the dip wash, eg, pesticide loss from the dip wash occurring at a greater rate than water loss, and is categorized as mechanical or chemical. In the case of sheep, mechanical stripping results from the fleece acting as a sieve toward the active ingredient, with the degree of filtration being primarily determined by particle size. Chemical stripping is due to the preferential absorption of pesticide by the fleece. To counteract stripping, a complex dip management regimen that involves reinforcement and ‘‘topping-up” is used. Reinforcement refers to the addition of undiluted chemical product to the dip without the addition of water, whereas topping-up refers to the addition of water and undiluted chemical product to the dip vat to return the volume to the starting level. Proper dip management also minimizes contamination of the dip with organic matter. This requires that the race leading to the vat is constructed of concrete or slats to remove dirt from the animals' feet and that animals be held in a yard overnight prior to dipping, during which time they are offered water but no food.

Hand spraying generally results in uneven coverage of animals and is considered an inefficient method of application. By comparison, recirculating and nonrecirculating spray races facilitate whole body spraying and wet cattle to the skin. The situation with sheep is different—the very short contact time in a spray race limits the uptake of insecticide, which means that the fleece seldom becomes saturated. Because of this, spray races should be used as an adjunct to shower or plunge dipping of sheep.

Shower dips are less labor intensive than plunge dips and are cheaper to operate. A typical shower dip consists of a sump containing the dip wash, a pump, and a showering pen constructed with a concrete floor and fitted with rotating and fixed nozzles. There are 2 types of shower dips: a conventional shower dip in which the sump volume is periodically maintained by adding fresh dip wash, and a constant replenishment shower dip in which a small-volume sump is continuously filled from a large-volume supply tank to maintain dip levels. Proper dip management requires attention to the factors described above for plunge dipping. In addition, all equipment must be functioning properly for the fleece to become saturated. Sheep should not be dipped (by either the plunge or shower method) until shearing wounds have healed to avoid clostridial infections or caseous lymphadenitis caused by Corynebacterium pseudo-tuberculosis. Moreover, the correct use of bacteriostats is recommended to prevent post-dipping lameness caused by Erysipelothrix insidiosa.

Insecticidal collars are plasticized polymer resins impregnated with an active ingredient. Collars for the control of ticks and fleas on dogs and cats release the active ingredient as a vapor, a dust, or a liquid, depending on the physicochemical properties of the chemical. Volatile liquid insecticides such as dichlorvos or naled are used in vapor-release collars. The insecticide distributes through the collar matrix as a vapor before being released. Powdered insecticides such as phosmet, stirofos, carbaryl, and propoxur are used in dust-release collars. Translocation of the active ingredient within the collar matrix leads to deposits forming at the surface; distribution of the insecticide to the animal depends on the physical activity of the animal. Nonvolatile liquid insecticides such as chlorfenvinphos or diazinon are used in liquid-release collars. The active ingredient distributes as a liquid in the collar matrix and to the surface, where it is released. The animal's activity plus the dissolution of lipophilic insecticides in skin secretions are important factors in the translocation of the insecticide from the collar to the animal.

Two types of insecticide-releasing ear tags for controlling flies on cattle are available. One is constructed from a polymer that provides structural support and acts as a release rate-controlling matrix. The other is a membrane-based ear tag that consists of an insecticidal reservoir with a relatively impermeable backing on one side and a rate-controlling membrane on the other. Both types rely on the animal's ear and head movements and grooming to transfer insecticide from the surface of the ear tag to the animal's skin or to other animals.

Back rubbers typically consist of burlap supported across lanes, gateways, or areas where cattle congregate. Back rubbers are charged by soaking thoroughly in oil-containing pesticide, typically a synthetic pyrethroid, an organophosphate, or a combination of the two. The oil retards evaporation of the insecticide and enhances adherence to the animal's coat.

Dust bags facilitate the self-treatment of cattle to control flies and lice. They are constructed of an inner porous bag containing the active ingredient, which is commonly a synthetic pyrethroid or an organophosphate, and an outer weatherproof skirt. Dust bags are hung in lanes or gateways so that passing cattle brush against them and receive a topical application of pesticide.

Inhaled Dosage Forms and Delivery Systems

Inhalational anesthetics are critical in the management of animal anesthesia. Currently, enflurane, halothane, isoflurane, methoxyflurane, and nitrous oxide are the most commonly used inhaled anesthetic agents. These agents are usually delivered to patients in a carrier gas that includes oxygen, using an anesthetic machine fitted with one or more vaporizers and a patient breathing circuit.

Inhalational therapy of airway disease is used to deliver high concentrations of drugs to the lungs while avoiding or minimizing systemic side effects. Additionally, the onset of pharmacologic action of inhaled agents is more rapid that when the drug is administered orally or by injection. The delivery systems used for inhalational therapy of airway disease in animals are nebulizers and metered-dose inhalers.

In the poultry industry, inhalation of aerosolized vaccines is a common method of immunizing flocks of birds.

Nanotechnology In Dosage Forms and Delivery Systems

Nanotechnology is a new enabling technology with the potential to revolutionize animal health. A nanomaterial is usually defined as a material engineered to be less than 100 nm in one more dimensions. A nanometer is one one-billionth of a meter, and a human hair is approximately 80,000 nm across. Chemicals at the nanoscale display physical and chemical behaviors that can differ markedly from those of the bulk chemical (eg, in optical properties, conductivity, or electromagnetism). From a public and environmental health and safety perspective, the perceived benefits of nano-technology must be balanced with any potential risks.

The main classes of nanomaterials are buckyballs (also known as fullerenes), nanotubes, quantum dots, dendrimers, nanoshells, and nanofibers. Potential applications of nanotechnology in animal health include disease diagnosis and treatment, “smart” drug delivery, and subcutaneous nanotube implants to measure reproductive hormones. Targeted drug delivery in the future might involve surface-coated biocompatible nanoparticles such as dendrimers formulated to contain drugs or genes for intracellular delivery. In addition, “smart” treatment delivery systems on the nano-scale would allow judicious use of smaller quantities of drugs than would otherwise be possible. In the case of antibiotics, for instance, such systems would use less drug, thereby relieving concerns surrounding the potential development of antibiotic-resistant strains of bacteria in humans and increasing food safety for the consumer.

Last full review/revision March 2012 by Philip T. Reeves, BVSc (Hons), PhD, FANZCVS

Copyright     © 2009-2015 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A.    Privacy    Terms of Use    Permissions